Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NUS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNu Skin stockholders approve equity plan adding 2.85M shares, extending term to 2036
Filed May 29, 2026 · Period ending May 28, 2026 · ~1 min read
Key Changes
-
medium
Stockholders approved amended equity incentive plan that increases share authorization by 2.85 million shares for employee and executive compensation awards, potentially diluting existing shareholders.
Item 5.07 verify on EDGAR → -
low
Plan termination date extended to May 28, 2036, giving company a 10-year window to grant stock options, restricted stock, and other equity-based compensation under this framework.
Item 5.07 verify on EDGAR → -
low
All annual meeting proposals passed including election of nine directors, advisory approval of executive compensation, and ratification of PricewaterhouseCoopers as 2026 auditor.
Item 5.07 verify on EDGAR →
Summary
Nu Skin's stockholders approved an amended equity incentive plan at the May 28, 2026 annual meeting, adding 2.85 million shares to the compensation pool and extending the plan through 2036. This represents a moderate expansion of the company's ability to grant stock-based awards to employees and executives, which will dilute existing shareholders over time as grants are made and vest. For retail investors, the key consideration is whether this dilution will be offset by improved employee retention and performance.
The 2.85 million share increase should be monitored against Nu Skin's total shares outstanding to assess the dilution impact. Watch upcoming proxy statements and quarterly filings for details on how aggressively management uses this expanded share pool and whether executive compensation remains aligned with shareholder returns. All other annual meeting items passed routinely, with no contested votes or governance concerns flagged.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 28, 2026, at the Nu Skin Enterprises, Inc. (the “Company”) 2026 Annual Meeting of Stockholders (the “Annual Meeting”), the Company’s stockholders approved and adopted the Company’s Amended and Restated 2024 Omnibus Incentive Plan (the “Amended and Restated Plan” or the “Plan”), which previously had been approved by the Company’s Board of Directors and its Compensation and Human Capital Committee subject to stockholder approval.
Stockholders approved the Amended and Restated 2024 Omnibus Incentive Plan at the 2026 Annual Meeting. The plan had already been approved by the Board of Directors and Compensation Committee, but required stockholder approval to become effective.
Added in current filing · verify on EDGAR →
Share Reserve. The Plan increases the share authorization by 2,850,000 shares.
The amended plan increases the number of shares available for equity compensation awards by 2,850,000 shares. This expands the pool of shares that can be granted to employees and executives as stock options, restricted stock, or other equity-based compensation.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Termination Date. The termination date is extended to the tenth anniversary of the effective date of the Amended and Restated Plan, which is May 28, 2036.
The plan's termination date has been extended to May 28, 2036, which is ten years from the effective date. This gives the company a decade-long window to grant equity compensation under this plan.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Item 5.07 — Submission of Matters to a Vote of Security Holders filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company’s stockholders approved the following proposals at the Annual Meeting on May 28, 2026:
•
Election of nine directors to serve until their successors are duly elected and qualified at the next annual meeting of stockholders or until their earlier death, resignation or removal;
•
Advisory approval of the Company’s executive compensation;
•
Approval of the Company’s Amended and Restated 2024 Omnibus Incentive Plan; and
•
Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026.
At the May 28, 2026 annual meeting, stockholders approved all four proposals on the ballot. These included electing nine directors, approving executive compensation on an advisory basis, approving an amended equity incentive plan, and ratifying PricewaterhouseCoopers as the independent auditor for 2026. All proposals passed with majority support.
Event · Item 9.01 — Financial Statements and Exhibits
Nu Skin filed an amended and restated 2024 Omnibus Incentive Plan with no material business impact disclosed.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Nu Skin Enterprises, Inc. Amended and Restated 2024 Omnibus Incentive Plan.
The company filed an amended and restated version of its 2024 Omnibus Incentive Plan as Exhibit 10.1. This is a routine filing updating the equity compensation plan framework for employees and executives. Without the full exhibit text, no material changes to plan terms, share reserves, or participant eligibility can be identified.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify